Free Trial
→ My next big call (under $1) (From Crypto 101 Media) (Ad)tc pixel Free SBFM Stock Alerts

Sunshine Biopharma (SBFM) Financials

Sunshine Biopharma logo
$2.84 +0.09 (+3.27%)
Closing price 11/12/2026 04:00 PM Eastern
Extended Trading
$2.80 -0.04 (-1.41%)
As of 04:59 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Sunshine Biopharma

Annual Income Statements for Sunshine Biopharma

This table shows Sunshine Biopharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -1.65 -3.50 -1.04 -2.16 -1.66 -2.78 -12 -27 -3.97 -6.66 -5.21
Consolidated Net Income / (Loss)		 -1.65 -3.50 -1.04 -2.16 -1.66 -2.78 -12 -27 -4.51 -5.13 -5.98
Net Income / (Loss) Continuing Operations		 -1.65 -3.50 -1.04 -2.14 -1.08 -2.78 -12 -27 -4.51 -5.13 -5.98
Total Pre-Tax Income 		-1.65 -3.50 -1.04 -2.14 -1.08 -2.78 -12 -27 -4.11 -5.37 -5.95
Total Operating Income		 -0.78 -0.99 -0.86 -1.16 -0.64 -0.58 -2.44 -27 -4.79 -5.81 -6.23
Total Gross Profit		 -0.38 -0.02 0.00 0.00 0.01 0.05 0.11 1.70 8.34 11 12
Total Revenue		 0.00 0.00 0.00 0.00 0.02 0.07 0.23 4.35 24 35 36
Operating Revenue		 0.00 0.00 0.00 0.00 0.02 0.07 0.23 4.35 24 35 36
Total Cost of Revenue		 0.38 0.02 0.00 0.00 0.01 0.03 0.12 2.65 16 24 24
Operating Cost of Revenue		 0.38 0.02 0.00 0.00 0.01 0.03 0.12 2.65 16 24 24
Total Operating Expenses		 0.40 0.97 0.86 1.16 0.65 0.62 2.55 29 13 16 18
Selling, General & Admin Expense		 0.09 0.07 0.08 0.15 0.09 0.08 0.12 0.34 3.46 5.00 6.13
Marketing Expense		 - - - - - - - 0.58 0.73 0.94 1.14
Research & Development Expense		 0.01 0.03 0.00 0.01 0.02 0.00 0.67 0.81 1.86 0.93 0.60
Depreciation Expense		 0.00 - - - 0.01 0.01 0.01 0.03 0.15 0.22 0.33
Other Operating Expenses / (Income)		 0.17 0.25 0.17 0.11 0.15 0.44 1.51 8.06 6.42 8.51 8.13
Impairment Charge		 - - - - - - - 18 - 0.00 1.75
Other Special Charges / (Income)		 0.13 0.56 0.60 0.87 0.38 0.09 0.23 0.55 0.51 0.88 0.39
Total Other Income / (Expense), net		 -0.87 -2.50 -0.18 -0.97 -0.44 -2.21 -10 0.49 0.67 0.44 0.27
Interest Expense		 0.87 1.98 0.18 1.02 0.42 2.22 10 0.03 0.14 0.01 0.00
Interest & Investment Income		 - - - 0.00 0.00 - 0.00 0.52 0.81 0.50 0.28
Other Income / (Expense), net		 0.00 -0.52 - 0.04 -0.01 0.01 0.00 -0.00 -0.00 -0.04 -0.01
Income Tax Expense		 - - - 0.00 0.00 0.00 0.00 0.23 0.40 -0.23 0.02
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 - - - - - - - -0.18 -0.53 1.53 -0.76
Basic Earnings per Share		 ($0.01) ($0.01) ($0.02) ($0.71) ($0.15) ($2.73) - - ($351.36) ($7.32) ($1.44)
Weighted Average Basic Shares Outstanding		 122.28M 424.87M 43.63M 3.05M 10.93M 1.02M 7.13M 22.59M 12.83K 701.75K 4.16M

Quarterly Income Statements for Sunshine Biopharma

This table shows Sunshine Biopharma's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -0.76 -1.83 -1.33 -0.35 -3.16 -1.15 -0.69 -1.49 -1.89 -1.52 -1.88
Consolidated Net Income / (Loss)		 -1.25 -1.28 -0.49 -1.20 -2.16 -1.18 -1.77 -0.88 -2.14 -1.24 -1.56
Net Income / (Loss) Continuing Operations		 -1.25 -1.28 -0.49 -1.20 -2.16 -1.18 -1.77 -0.88 -2.14 -1.24 -1.56
Total Pre-Tax Income 		-1.03 -1.26 -0.84 -0.98 -2.29 -1.22 -1.98 -1.02 -1.73 -1.24 -1.56
Total Operating Income		 -1.16 -1.35 -1.27 -1.11 -2.09 -1.30 -2.05 -1.09 -1.79 -1.40 -1.61
Total Gross Profit		 2.57 2.35 2.36 2.87 3.09 2.73 3.42 3.07 3.03 2.18 2.43
Total Revenue		 7.68 7.54 9.30 8.44 9.59 8.90 9.41 9.42 8.58 8.09 9.26
Operating Revenue		 7.68 7.54 9.30 8.44 9.59 8.90 9.41 9.42 8.58 8.09 9.26
Total Cost of Revenue		 5.11 5.19 6.95 5.57 6.50 6.17 5.99 6.34 5.55 5.91 6.84
Operating Cost of Revenue		 5.11 5.19 6.95 5.57 6.50 6.17 5.99 6.34 5.55 5.91 6.84
Total Operating Expenses		 3.73 3.70 3.62 3.97 5.18 4.03 5.48 4.16 4.82 3.58 4.04
Selling, General & Admin Expense		 2.39 1.31 0.86 1.13 1.71 1.58 1.62 0.91 2.02 1.19 1.25
Marketing Expense		 0.23 0.20 0.26 0.28 0.20 0.40 0.20 0.24 0.31 0.25 0.21
Research & Development Expense		 0.82 0.22 0.44 0.13 0.15 0.22 0.20 0.12 0.07 0.03 0.01
Depreciation Expense		 0.04 0.04 0.05 0.06 0.07 0.06 0.07 0.10 0.10 0.08 0.08
Other Operating Expenses / (Income)		 0.13 1.71 1.80 2.25 2.74 1.74 2.26 2.05 2.08 1.94 2.16
Impairment Charge		 - - 0.00 0.00 - - 1.06 0.55 - - 0.00
Other Special Charges / (Income)		 0.13 0.22 0.22 0.12 0.31 0.03 0.06 0.19 0.10 0.09 0.33
Total Other Income / (Expense), net		 0.13 0.09 0.43 0.12 -0.20 0.08 0.07 0.07 0.06 0.15 0.05
Interest & Investment Income		 0.19 0.14 0.14 0.11 0.10 0.08 0.07 0.08 0.06 0.05 0.05
Other Income / (Expense), net		 -0.00 -0.01 0.29 0.02 -0.34 0.00 0.00 -0.01 -0.00 0.10 -0.00
Income Tax Expense		 0.22 0.02 -0.34 0.22 -0.13 -0.04 -0.21 -0.14 0.41 0.00 0.00
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 -0.49 0.54 0.84 -0.85 1.00 -0.03 -1.08 0.60 -0.26 0.28 0.32
Basic Earnings per Share		 ($59.14) ($2.00) ($9.94) ($0.94) ($4.50) ($0.44) ($3.94) ($0.19) ($0.45) ($0.25) ($1.15)
Weighted Average Basic Shares Outstanding		 12.83K 641.31K 49.73K 1.27M 701.75K 2.70M 449.61K 4.56M 4.16M 4.91M 1.37M
Weighted Average Diluted Shares Outstanding		 12.83K 641.31K 1.22M 2.00M 2.71M 4.56M 4.56M 4.91M 0.00 5.01M 3.88M
Weighted Average Basic & Diluted Shares Outstanding		 99.45M 18.95M 1.22M 2.00M 2.71M 4.56M 4.56M 4.91M 0.00 5.01M 3.88M

Annual Cash Flow Statements for Sunshine Biopharma

This table details how cash moves in and out of Sunshine Biopharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -0.09 0.01 0.04 0.00 -0.07 0.95 1.08 20 -6.01 -5.56 -1.42
Net Cash From Operating Activities		 -0.87 -0.31 -0.54 -0.51 -0.50 -0.66 -1.83 -5.25 -8.78 -13 -5.33
Net Cash From Continuing Operating Activities		 -0.87 -0.31 -0.54 -0.51 -0.50 -0.66 -1.83 -5.25 -8.78 -13 -5.33
Net Income / (Loss) Continuing Operations		 -1.65 -3.50 -1.04 -2.16 -1.66 -2.78 -12 -27 -4.51 -5.13 -5.98
Consolidated Net Income / (Loss)		 -1.65 -3.50 -1.04 -2.16 -1.66 -2.78 -12 -27 -4.51 -5.13 -5.98
Depreciation Expense		 0.00 0.06 0.01 0.05 0.01 0.01 0.01 0.03 0.15 0.22 0.33
Non-Cash Adjustments To Reconcile Net Income		 0.70 3.21 0.51 1.54 1.18 2.16 11 18 0.00 -2.23 1.77
Changes in Operating Assets and Liabilities, net		 0.08 -0.09 -0.02 0.05 -0.03 -0.04 -0.11 3.15 -4.42 -5.38 -1.46
Net Cash From Investing Activities		 -0.62 -0.00 -0.08 -0.01 -0.02 -0.00 0.00 -15 -0.66 -1.98 -0.84
Net Cash From Continuing Investing Activities		 -0.62 -0.00 -0.08 -0.01 -0.02 -0.00 0.00 -15 -0.66 -1.98 -0.84
Purchase of Property, Plant & Equipment		 -0.00 -0.00 -0.00 -0.02 -0.00 -0.00 0.00 -0.19 -0.08 -1.66 -0.17
Acquisitions		 -0.62 - - - - - 0.00 -14 -0.71 -0.32 -0.66
Net Cash From Financing Activities		 1.40 0.32 0.67 0.53 0.44 1.61 2.90 39 3.43 8.94 4.75
Net Cash From Continuing Financing Activities		 1.40 0.32 0.67 0.53 0.44 1.61 2.90 39 3.43 8.94 4.75
Repurchase of Common Equity		 - - - - - - - -0.10 -0.54 -3.14 0.00
Issuance of Common Equity		 0.24 0.10 0.06 - - - 0.00 30 4.09 8.52 1.83
Other Financing Activities, net		 0.93 0.09 -0.09 0.09 0.03 - 0.06 11 -0.12 3.56 2.92
Cash Interest Paid		 0.00 0.01 0.02 0.02 0.00 0.02 0.04 0.05 - 0.01 0.00
Cash Income Taxes Paid		 0.00 0.00 - - 0.00 0.00 0.00 - 0.00 0.58 0.00

Quarterly Cash Flow Statements for Sunshine Biopharma

This table details how cash moves in and out of Sunshine Biopharma's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 -2.99 1.54 -5.15 -0.07 -1.88 -1.55 1.85 -0.77 -0.94 -2.18 6.88
Net Cash From Operating Activities		 -2.69 -3.19 -4.58 -1.36 -3.41 -1.70 -1.27 -0.73 -1.62 -2.07 -0.92
Net Cash From Continuing Operating Activities		 -2.69 -3.19 -4.58 -1.36 -3.41 -1.70 -1.27 -0.73 -1.62 -2.07 -0.92
Net Income / (Loss) Continuing Operations		 -1.25 -1.28 -0.49 -1.20 -2.16 -1.18 -1.77 -0.88 -2.14 -1.24 -1.56
Consolidated Net Income / (Loss)		 -1.25 -1.28 -0.49 -1.20 -2.16 -1.18 -1.77 -0.88 -2.14 -1.24 -1.56
Depreciation Expense		 0.04 0.04 0.05 0.06 0.07 0.06 0.07 0.10 0.10 0.08 0.08
Non-Cash Adjustments To Reconcile Net Income		 0.17 0.01 -2.55 -0.09 0.39 0.02 1.06 0.42 0.29 -0.00 0.10
Changes in Operating Assets and Liabilities, net		 -1.65 -1.96 -1.59 -0.14 -1.70 -0.60 -0.64 -0.37 0.14 -0.90 0.47
Net Cash From Investing Activities		 -0.27 -0.67 -0.54 -0.67 -0.10 -0.21 -0.55 -0.12 -0.05 -0.10 -0.01
Net Cash From Continuing Investing Activities		 -0.27 -0.67 -0.54 -0.67 -0.10 -0.21 -0.55 -0.12 -0.05 -0.10 -0.01
Purchase of Property, Plant & Equipment		 0.38 -0.06 -0.97 -0.52 -0.10 -0.01 -0.16 -0.01 0.00 -0.01 -0.01
Acquisitions		 -0.69 -0.64 0.40 -0.09 0.00 -0.20 -0.39 -0.03 -0.04 -0.10 0.00
Net Cash From Financing Activities		 -0.03 5.40 -0.03 1.95 1.62 0.36 3.67 0.08 0.72 0.00 7.80
Net Cash From Continuing Financing Activities		 -0.03 5.40 -0.03 1.95 1.62 0.36 3.67 0.08 0.72 0.00 7.80
Other Financing Activities, net		 -0.03 0.02 -0.03 1.95 1.62 0.36 1.84 0.08 0.72 0.00 2.72

Annual Balance Sheets for Sunshine Biopharma

This table presents Sunshine Biopharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 0.67 0.06 0.26 1.15 0.10 1.05 2.20 29 27 31 30
Total Current Assets		 0.05 0.06 0.12 1.10 0.07 1.03 2.20 27 25 26 27
Cash & Equivalents		 0.05 0.06 0.11 0.11 0.04 0.99 2.05 22 16 9.69 9.12
Accounts Receivable		 - - 0.00 0.00 0.00 0.00 0.01 1.91 2.55 3.87 3.46
Inventories, net		 - - - 0.00 0.02 0.02 0.11 3.29 5.73 11 13
Prepaid Expenses		 0.00 0.00 0.01 0.00 0.00 0.00 0.03 0.28 0.31 1.13 0.80
Other Current Assets		 - - - - 0.01 0.01 0.01 - - - 0.00
Plant, Property, & Equipment, net		 0.00 0.01 0.06 0.05 0.03 0.02 0.01 0.39 0.37 0.55 0.56
Total Noncurrent Assets		 0.62 0.00 0.08 0.00 0.00 0.00 0.00 1.54 2.09 4.05 2.67
Intangible Assets		 0.62 0.00 0.00 0.00 0.00 0.00 0.00 0.78 1.44 3.02 1.89
Other Noncurrent Operating Assets		 - 0.00 0.08 - - - 0.00 0.76 0.65 0.94 0.78
Total Liabilities & Shareholders' Equity		 0.67 0.06 0.26 1.15 0.10 1.05 2.20 29 27 31 30
Total Liabilities		 1.27 0.27 0.83 1.20 0.83 2.00 1.99 7.62 6.14 7.06 7.04
Total Current Liabilities		 1.27 0.27 0.75 0.91 0.83 1.05 0.09 6.93 5.55 6.31 6.44
Accounts Payable		 0.13 0.03 0.02 0.14 0.10 0.06 0.04 2.80 2.59 5.54 5.66
Current Deferred & Payable Income Tax Liabilities		 - - - - - - 0.00 0.37 0.30 0.27 0.27
Other Current Liabilities		 - - - - - - 0.00 3.76 2.67 0.50 0.51
Total Noncurrent Liabilities		 0.00 0.00 0.08 0.29 0.00 0.95 1.90 0.69 0.59 0.74 0.60
Other Noncurrent Operating Liabilities		 0.00 - - - - - 0.00 0.64 0.54 0.74 0.60
Total Equity & Noncontrolling Interests		 -0.60 -0.21 -0.57 -0.06 -0.74 -0.95 0.21 22 21 24 23
Total Preferred & Common Equity		 -0.60 -0.21 -0.57 -0.06 -0.74 -0.95 0.21 22 21 24 23
Preferred Stock		 0.00 0.05 0.05 0.05 0.05 0.10 0.10 0.00 0.00 0.01 0.01
Total Common Equity		 -0.60 -0.26 -0.62 -0.11 -0.79 -1.05 0.11 22 21 23 23
Common Stock		 8.43 12 13 16 17 19 33 81 84 93 98
Retained Earnings		 -9.08 -13 -14 -16 -17 -20 -33 -59 -64 -69 -75
Accumulated Other Comprehensive Income / (Loss)		 0.00 0.00 0.00 -0.00 -0.00 -0.00 -0.02 0.16 0.70 -0.83 -0.07

Quarterly Balance Sheets for Sunshine Biopharma

This table presents Sunshine Biopharma's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 32 29 30 29 32 31 28 34
Total Current Assets		 29 26 26 24 28 28 25 31
Cash & Equivalents		 17 12 12 8.12 10 9.31 6.91 14
Accounts Receivable		 2.83 3.97 3.22 3.45 3.59 4.16 4.01 4.04
Inventories, net		 7.70 8.49 9.82 12 13 14 13 12
Prepaid Expenses		 0.87 1.78 0.74 0.98 0.94 0.44 0.62 0.48
Other Current Assets		 - - - 0.07 - - 0.07 0.28
Plant, Property, & Equipment, net		 0.40 0.54 0.59 0.52 0.64 0.60 0.52 0.48
Total Noncurrent Assets		 2.67 3.01 3.48 4.19 3.48 2.92 2.63 2.49
Intangible Assets		 2.07 2.45 2.94 3.19 2.49 2.01 1.92 1.84
Other Noncurrent Operating Assets		 0.60 0.56 0.54 0.90 0.89 0.82 0.71 0.65
Total Liabilities & Shareholders' Equity		 32 29 30 29 32 31 28 34
Total Liabilities		 7.08 5.81 5.02 6.48 6.28 7.29 6.41 6.09
Total Current Liabilities		 6.53 5.30 4.53 5.76 5.57 6.65 5.88 5.62
Accounts Payable		 3.62 4.93 4.16 5.02 4.80 6.14 5.10 4.85
Current Deferred & Payable Income Tax Liabilities		 0.25 0.25 0.25 0.23 0.26 0.00 0.27 0.27
Other Current Liabilities		 2.66 0.11 0.12 0.51 0.52 0.51 0.51 0.50
Total Noncurrent Liabilities		 0.55 0.51 0.49 0.72 0.71 0.64 0.54 0.48
Other Noncurrent Operating Liabilities		 0.50 0.46 0.44 0.72 0.71 0.64 0.54 0.48
Total Equity & Noncontrolling Interests		 25 23 25 23 26 24 22 28
Total Preferred & Common Equity		 25 23 25 23 26 24 22 28
Preferred Stock		 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
Total Common Equity		 25 23 25 23 26 24 22 28
Common Stock		 90 90 92 94 97 97 98 106
Retained Earnings		 -65 -66 -67 -70 -72 -73 -76 -78
Accumulated Other Comprehensive Income / (Loss)		 0.15 -0.68 0.17 -0.80 0.28 -0.32 -0.34 -0.66

Annual Metrics And Ratios for Sunshine Biopharma

This table displays calculated financial ratios and metrics derived from Sunshine Biopharma's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 137,549,992.00 686,399,858.00 918,736,498.00 1,632,980,943.00 520,130,745.00 332,419,296.00 0.00 22,585,632.00 25,678,290.00 1,999,660.00 4,905,945.00
DEI Adjusted Shares Outstanding		 68,775.00 343,200.00 459,368.00 816,490.00 260,065.00 166,210.00 0.00 11,293.00 12,839.00 199,966.00 490,594.00
DEI Earnings Per Adjusted Shares Outstanding		 -24.03 -10.19 -2.26 -2.64 -6.38 -16.75 0.00 -2,351.85 -309.35 -33.31 -10.62
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% -100.00% 0.00% 0.00% 0.00% 238.10% 219.88% 1,802.41% 454.42% 44.75% 4.11%
EBITDA Growth		 55.80% -87.63% 41.57% -26.20% 40.22% 13.53% -337.42% -1,011.34% 82.81% -21.49% -4.79%
EBIT Growth		 55.55% -94.40% 43.47% -30.98% 41.62% 13.20% -328.85% -1,006.57% 82.28% -22.37% -6.46%
NOPAT Growth		 55.54% -27.28% 13.69% -35.83% 44.89% 10.09% -322.99% -1,006.53% 82.28% -21.46% -7.14%
Net Income Growth		 14.54% -111.55% 70.25% -107.28% 23.00% -67.69% -346.70% -115.05% 83.15% -13.94% -16.39%
EPS Growth		 66.67% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Growth		 -61.09% 63.79% -73.00% 5.65% 3.32% -32.57% -178.28% -186.93% -67.20% -42.73% 57.44%
Free Cash Flow Firm Growth		 11.60% 83.41% -320.92% 20.98% 15.82% 12.87% -319.98% -915.59% 54.46% -53.22% 65.61%
Invested Capital Growth		 1,524.91% -104.27% 717.07% -169.07% 56.51% 81.44% 1,675.81% -273.26% 2,571.51% 181.06% 0.73%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% -100.00% 126.20% 32.36% 33.33% 785.27% 18.38% 5.81% -2.73%
EBITDA Q/Q Growth		 14.96% -92.44% 45.83% 6.92% -31.86% -19.98% 2.60% -590.40% 82.74% -28.25% 10.19%
EBIT Q/Q Growth		 14.50% -88.17% 46.10% 6.30% -30.30% -19.41% 2.60% -589.39% 82.27% -27.52% 9.27%
NOPAT Q/Q Growth		 14.47% -19.47% 16.87% 2.83% -23.56% -19.15% 2.54% -589.36% 82.27% -18.90% 4.55%
Net Income Q/Q Growth		 -17.96% -16.15% 46.74% -6.27% -3.62% -32.77% 12.34% -942.66% 83.17% -21.49% 0.29%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 83.17% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 -12.31% 49.79% -48.82% 15.41% -2.44% -81.84% 5.75% -58.38% -5.32% -6.06% 25.20%
Free Cash Flow Firm Q/Q Growth		 -63.01% 84.65% -242.79% 65.25% -184.59% -17.45% -1.27% -640.12% 61.84% 1.65% 32.20%
Invested Capital Q/Q Growth		 2,232.80% -103.79% 134.08% -109.74% -40.11% -276.67% 95.81% -15.76% 57.67% 7.24% -6.57%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 -22,416.45% 0.00% 0.00% 0.00% 47.68% 63.80% 48.42% 39.04% 34.61% 30.60% 33.76%
EBITDA Margin		 -45,422.83% 0.00% 0.00% 0.00% -3,038.29% -777.09% -1,062.64% -620.77% -19.24% -16.15% -16.26%
Operating Margin		 -45,683.67% 0.00% 0.00% 0.00% -3,037.91% -807.83% -1,068.24% -621.33% -19.86% -16.67% -17.15%
EBIT Margin		 -45,671.72% 0.00% 0.00% 0.00% -3,103.51% -796.78% -1,068.22% -621.35% -19.86% -16.79% -17.17%
Profit (Net Income) Margin		 -96,774.47% 0.00% 0.00% 0.00% -7,860.85% -3,898.74% -5,444.41% -615.44% -18.70% -14.72% -16.46%
Tax Burden Percent		 100.00% 100.00% 100.12% 100.85% 154.01% 100.00% 99.53% 100.88% 109.61% 95.63% 100.36%
Interest Burden Percent		 211.89% 230.59% 121.20% 190.42% 164.46% 489.31% 512.09% 98.18% 85.90% 91.68% 95.49%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -237.16% 0.00% 0.00% 0.00% 0.00% 0.00% -3,177.91% 0.00% -142.05% -43.45% -31.44%
ROIC Less NNEP Spread (ROIC-NNEP)		 -390.31% 0.00% 0.00% 0.00% 0.00% 0.00% -5,700.23% 0.00% -135.99% -35.24% -14.25%
Return on Net Nonoperating Assets (RNNOA)		 572.90% 0.00% 0.00% 0.00% 0.00% 0.00% 6,524.75% 0.00% 121.01% 20.48% 5.76%
Return on Equity (ROE)		 335.74% 866.86% 265.68% 685.46% 419.72% 329.43% 3,346.84% -244.92% -21.04% -22.97% -25.68%
Cash Return on Invested Capital (CROIC)		 -217.27% 0.00% -575.51% 0.00% 0.00% 0.00% -1,594.47% 0.00% -172.20% -138.48% -32.17%
Operating Return on Assets (OROA)		 -191.03% 0.00% 0.00% 0.00% -105.32% -99.51% -150.23% -171.73% -16.91% -20.23% -20.56%
Return on Assets (ROA)		 -404.79% 0.00% 0.00% 0.00% -266.77% -486.89% -765.71% -170.09% -15.93% -17.73% -19.71%
Return on Common Equity (ROCE)		 335.74% 920.59% 299.61% 794.41% 472.78% 358.67% 4,247.53% -243.79% -21.04% -22.96% -25.66%
Return on Equity Simple (ROE_SIMPLE)		 276.85% 1,667.47% 181.43% 3,867.33% 225.77% 291.58% 0.00% -123.66% -21.25% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -0.55 -0.70 -0.60 -0.82 -0.45 -0.40 -1.71 -19 -3.35 -4.07 -4.36
NOPAT Margin		 -31,978.57% 0.00% 0.00% 0.00% -2,126.53% -565.48% -747.77% -434.93% -13.90% -11.67% -12.01%
Net Nonoperating Expense Percent (NNEP)		 153.15% 437.41% 98.64% 400.63% 366.09% 289.63% 2,522.32% -71.56% -6.07% -8.20% -17.19%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -15.80% -17.31% -18.92%
Cost of Revenue to Revenue		 22,516.45% 0.00% 0.00% 0.00% 52.32% 36.20% 51.58% 60.96% 65.39% 69.41% 66.24%
SG&A Expenses to Revenue		 5,002.93% 0.00% 0.00% 0.00% 422.58% 114.16% 51.84% 7.85% 14.35% 14.35% 16.90%
R&D to Revenue		 506.85% 0.00% 0.00% 0.00% 71.99% 2.42% 294.28% 18.68% 7.70% 2.68% 1.66%
Operating Expenses to Revenue		 23,267.21% 0.00% 0.00% 0.00% 3,085.59% 871.64% 1,116.65% 660.38% 54.47% 47.26% 50.91%
Earnings before Interest and Taxes (EBIT)		 -0.78 -1.52 -0.86 -1.12 -0.66 -0.57 -2.44 -27 -4.79 -5.86 -6.23
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -0.78 -1.46 -0.85 -1.07 -0.64 -0.55 -2.43 -27 -4.64 -5.63 -5.90
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 0.00 6.85 0.67 0.33 0.26 0.26
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 6.85 0.69 0.35 0.29 0.29
Price to Revenue (P/Rev)		 12,079.92 0.00 0.00 0.00 11.08 6.98 3.35 3.33 0.29 0.17 0.17
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 43.85 0.00 1,060.60 0.00 0.00 0.00 6.27 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 12,717.96 0.00 0.00 0.00 45.41 21.31 3.15 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 -1.91 -1.13 -1.40 -17.09 -0.97 -2.00 8.98 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 -0.14 -5.20 0.00 -0.99 8.98 0.00 0.00 0.00 0.00
Financial Leverage		 -1.47 -1.59 -1.14 -1.06 -0.84 -0.97 -1.14 -1.00 -0.89 -0.58 -0.40
Leverage Ratio		 -0.83 -0.91 -0.41 -2.23 -1.57 -0.68 -4.37 1.44 1.32 1.30 1.30
Compound Leverage Factor		 -1.76 -2.11 -0.50 -4.25 -2.59 -3.31 -22.38 1.41 1.13 1.19 1.24
Debt to Total Capital		 209.85% 868.95% 350.43% 106.22% -3,610.88% 199.64% 89.98% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 209.85% 868.95% 315.61% 73.90% -3,610.88% 100.61% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 34.81% 32.32% 0.00% 99.03% 89.98% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 183.34% 21.84% 5.58% -252.31% 10.44% 4.74% 0.00% 0.00% 0.06% 0.06%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -109.85% -952.29% -272.26% -11.79% 3,963.19% -110.08% 5.29% 100.00% 100.00% 99.94% 99.94%
Debt to EBITDA		 -1.47 -0.16 -0.94 -0.89 -1.12 -3.45 -0.78 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 -1.40 -0.12 -0.82 -0.78 -1.05 -1.66 0.06 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 -0.09 -0.27 0.00 -1.71 -0.78 0.00 0.00 0.00 0.00
Debt to NOPAT		 -2.09 -0.34 -1.34 -1.17 -1.59 -4.74 -1.11 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 -2.00 -0.26 -1.16 -1.03 -1.50 -2.29 0.09 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 -0.13 -0.36 0.00 -2.35 -1.11 0.00 0.00 0.00 0.00
Altman Z-Score		 -15.13 -129.76 11.54 -21.48 -279.75 -28.68 -22.93 -3.77 -1.44 -1.37 -1.64
Noncontrolling Interest Sharing Ratio		 0.00% -6.20% -12.77% -15.90% -12.64% -8.87% -26.91% 0.46% 0.00% 0.03% 0.06%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.04 0.21 0.16 1.21 0.08 0.98 24.07 3.94 4.48 4.11 4.17
Quick Ratio		 0.04 0.21 0.14 0.12 0.05 0.94 22.50 3.43 3.39 2.15 1.95
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -1.08 -0.18 -0.75 -0.59 -0.50 -0.44 -1.83 -19 -8.46 -13 -4.46
Operating Cash Flow to CapEx		 -18,102.32% -9,135.85% -14,618.61% -2,720.46% -57,650.93% -55,188.83% 0.00% -2,705.59% -10,668.70% -755.85% -3,055.21%
Free Cash Flow to Firm to Interest Expense		 -1.23 -0.09 -4.14 -0.59 -1.18 -0.20 -0.18 -650.80 -61.64 -1,477.97 0.00
Operating Cash Flow to Interest Expense		 -0.99 -0.16 -2.99 -0.51 -1.17 -0.30 -0.18 -183.77 -63.91 -1,427.49 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -1.00 -0.16 -3.01 -0.52 -1.18 -0.30 -0.18 -190.56 -64.51 -1,616.35 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.03 0.12 0.14 0.28 0.85 1.20 1.20
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 60.88 47.03 4.53 10.79 10.86 9.91
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 1.30 1.82 1.56 3.49 2.85 1.94
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.54 2.75 17.18 21.66 63.39 76.49 65.81
Accounts Payable Turnover		 4.75 0.25 0.00 0.00 0.09 0.32 2.23 1.86 5.85 5.96 4.29
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 6.00 7.76 80.63 33.82 33.60 36.84
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 280.18 200.45 233.93 104.55 128.28 187.81
Days Payable Outstanding (DPO)		 76.80 1,474.98 0.00 0.00 3,857.75 1,127.97 163.89 196.05 62.42 61.29 85.04
Cash Conversion Cycle (CCC)		 -76.80 0.00 0.00 0.00 -3,857.75 -841.80 44.33 118.51 75.95 100.59 139.60
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.50 -0.02 0.13 -0.09 -0.04 -0.01 0.11 -0.20 4.92 14 14
Invested Capital Turnover		 0.01 0.00 0.00 0.00 -0.33 -3.07 4.25 -103.36 10.22 3.72 2.62
Increase / (Decrease) in Invested Capital		 0.53 -0.52 0.15 -0.22 0.05 0.03 0.12 -0.31 5.11 8.90 0.10
Enterprise Value (EV)		 22 103 139 2.53 0.96 1.52 0.72 -7.37 -9.32 -3.67 -3.08
Market Capitalization		 21 103 138 1.63 0.23 0.50 0.77 14 6.97 6.00 6.03
Book Value per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.02 $0.96 $0.83 $11.75 $4.69
Tangible Book Value per Share		 ($0.01) $0.00 $0.00 $0.00 $0.00 $0.00 $0.02 $0.92 $0.77 $10.24 $4.31
Total Capital		 0.54 0.03 0.23 0.90 -0.02 0.96 2.11 22 21 24 23
Total Debt		 1.14 0.24 0.80 0.95 0.72 1.91 1.90 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.08 0.29 0.00 0.95 1.90 0.00 0.00 0.00 0.00
Net Debt		 1.09 0.18 0.69 0.84 0.68 0.92 -0.15 -22 -16 -9.69 -9.12
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.02 0.00 0.00 0.00 0.19 0.08 1.66 0.17
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.13 -0.04 -0.02 0.74 -0.09 -0.05 0.06 -1.45 3.05 9.96 11
Debt-free Net Working Capital (DFNWC)		 -0.08 0.02 0.09 0.85 -0.05 0.94 2.10 20 19 20 20
Net Working Capital (NWC)		 -1.22 -0.22 -0.63 0.19 -0.77 -0.03 2.10 20 19 20 20
Net Nonoperating Expense (NNE)		 1.11 2.80 0.44 1.34 1.21 2.38 11 7.84 1.16 1.07 1.62
Net Nonoperating Obligations (NNO)		 1.09 0.19 0.70 -0.03 0.70 0.95 -0.10 -22 -16 -9.69 -9.12
Total Depreciation and Amortization (D&A)		 0.00 0.06 0.01 0.05 0.01 0.01 0.01 0.03 0.15 0.22 0.33
Debt-free, Cash-free Net Working Capital to Revenue		 -7,413.52% 0.00% 0.00% 0.00% -439.25% -71.61% 26.02% -33.25% 12.64% 28.57% 31.09%
Debt-free Net Working Capital to Revenue		 -4,439.40% 0.00% 0.00% 0.00% -247.49% 1,314.60% 921.35% 469.01% 80.27% 56.35% 56.22%
Net Working Capital to Revenue		 -71,217.62% 0.00% 0.00% 0.00% -3,635.44% -35.52% 921.35% 469.01% 80.27% 56.35% 56.22%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($20.00) ($20.00) $0.00 ($80.00) ($300.00) ($20.00) ($9,520.00) $0.00 $0.00 ($73.20) ($14.40)
Adjusted Weighted Average Basic Shares Outstanding		 61.14K 212.44K 436.34K 30.47K 5.47K 102.05K 1.31K 11.29K 49.73K 70.18K 415.71K
Adjusted Diluted Earnings per Share		 ($20.00) ($20.00) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 ($73.20) $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 111.44K 0.00 474.01K 26.95K 0.00 232.50K 3.57K 11.29K 49.73K 70.18K 0.00
Adjusted Basic & Diluted Earnings per Share		 ($20.00) ($20.00) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 111.44K 0.00 474.01K 26.95K 0.00 232.50K 3.57K 11.29K 49.73K 270.75K 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -0.45 -0.31 -0.18 -0.21 -0.18 -0.34 -1.55 -5.69 -2.99 -3.46 -2.87
Normalized NOPAT Margin		 -26,637.38% 0.00% 0.00% 0.00% -852.38% -477.67% -676.48% -130.86% -12.42% -9.91% -7.89%
Pre Tax Income Margin		 -96,774.47% 0.00% 0.00% 0.00% -5,104.18% -3,898.74% -5,470.21% -610.07% -17.06% -15.40% -16.40%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -0.89 -0.77 -4.72 -1.11 -1.55 -0.26 -0.24 -945.42 -34.85 -667.45 0.00
NOPAT to Interest Expense		 -0.63 -0.35 -3.30 -0.80 -1.06 -0.18 -0.17 -661.78 -24.40 -463.70 0.00
EBIT Less CapEx to Interest Expense		 -0.90 -0.77 -4.74 -1.12 -1.55 -0.26 -0.24 -952.21 -35.45 -856.31 0.00
NOPAT Less CapEx to Interest Expense		 -0.63 -0.35 -3.32 -0.82 -1.06 -0.18 -0.17 -668.58 -24.99 -652.56 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.37% -12.01% -61.15% 0.00%

Quarterly Metrics And Ratios for Sunshine Biopharma

This table displays calculated financial ratios and metrics derived from Sunshine Biopharma's official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 25,678,290.00 99,452,865.00 18,945,052.00 2,348,682.00 1,999,660.00 2,707,541.00 4,555,945.00 4,555,945.00 4,905,945.00 4,905,945.00 5,005,945.00
DEI Adjusted Shares Outstanding		 12,839.00 49,726.00 947,253.00 2,348,682.00 199,966.00 270,754.00 455,594.00 4,555,945.00 490,594.00 490,594.00 500,594.00
DEI Earnings Per Adjusted Shares Outstanding		 -59.08 -36.75 -1.40 -0.15 -15.79 -4.26 -1.51 -0.33 -3.84 -3.10 -3.75
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 94.94% 54.09% 67.30% 41.59% 24.93% 18.04% 1.15% 11.64% -10.61% -9.13% -1.56%
EBITDA Growth		 95.20% 26.78% 4.94% -38.31% -110.73% 6.34% -112.73% 2.54% 28.37% 1.22% 22.49%
EBIT Growth		 95.02% 25.84% 3.20% -40.00% -108.68% 4.50% -109.09% -0.50% 26.24% 0.23% 21.43%
NOPAT Growth		 95.02% 26.16% -25.09% -41.94% -79.45% 4.06% -62.00% 1.78% 14.23% -7.71% 21.50%
Net Income Growth		 94.68% 24.59% 45.21% -83.86% -72.65% 8.10% -258.25% 26.21% 0.80% -5.43% 11.68%
EPS Growth		 94.68% 24.59% 0.00% 0.00% 92.39% 0.00% 0.00% 0.00% 90.00% 0.00% 0.00%
Operating Cash Flow Growth		 -19.72% -72.16% -21.17% -196.66% -26.60% 46.78% 72.18% 46.35% 52.54% -22.25% 27.91%
Free Cash Flow Firm Growth		 63.04% -540.75% -142.61% -174.81% -74.77% 1.17% 49.81% 73.69% 86.93% 87.62% 109.63%
Invested Capital Growth		 2,571.51% 5,360.16% 255.91% 313.22% 181.06% 97.39% 27.83% 15.62% 0.73% 0.18% -10.34%
Revenue Q/Q Growth		 28.91% -1.81% 23.37% -9.33% 13.75% -7.23% 5.72% 0.07% -8.92% -5.69% 14.53%
EBITDA Q/Q Growth		 -50.98% -17.23% 29.14% -10.28% -130.04% 47.89% -60.93% 49.48% -69.07% 28.14% -26.28%
EBIT Q/Q Growth		 -49.21% -16.63% 27.62% -11.15% -122.41% 46.63% -58.47% 46.58% -63.23% 27.81% -24.81%
NOPAT Q/Q Growth		 -49.20% -16.13% 6.09% 12.77% -88.63% 37.91% -58.57% 47.11% -64.73% 22.03% -15.57%
Net Income Q/Q Growth		 -91.87% -2.70% 61.50% -142.32% -80.18% 45.34% -50.10% 50.09% -142.24% 41.90% -25.74%
EPS Q/Q Growth		 0.00% -2.70% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 -488.18% -18.42% -43.72% 70.37% -151.02% 50.22% 24.87% 42.85% -122.04% -28.22% 55.70%
Free Cash Flow Firm Q/Q Growth		 -54.58% -38.25% -16.38% -10.49% 1.69% 21.82% 40.90% 42.09% 51.16% 25.95% 145.96%
Invested Capital Q/Q Growth		 57.67% 50.26% 62.90% 7.07% 7.24% 5.53% 5.50% -3.16% -6.57% 4.95% -5.57%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 33.44% 31.22% 25.33% 33.98% 32.24% 30.67% 36.37% 32.64% 35.31% 26.96% 26.20%
EBITDA Margin		 -14.59% -17.42% -10.01% -12.17% -24.61% -13.82% -21.04% -10.62% -19.72% -15.03% -16.57%
Operating Margin		 -15.14% -17.91% -13.63% -13.12% -21.75% -14.56% -21.83% -11.54% -20.87% -17.25% -17.41%
EBIT Margin		 -15.14% -17.99% -10.55% -12.94% -25.29% -14.55% -21.81% -11.64% -20.87% -15.98% -17.41%
Profit (Net Income) Margin		 -16.28% -17.02% -5.31% -14.20% -22.49% -13.25% -18.82% -9.39% -24.96% -15.38% -16.88%
Tax Burden Percent		 121.39% 101.77% 58.99% 121.90% 94.37% 96.71% 89.44% 86.54% 123.57% 100.00% 100.00%
Interest Burden Percent		 88.54% 93.00% 85.36% 90.05% 94.23% 94.18% 96.46% 93.13% 96.79% 96.25% 96.97%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -108.30% -89.15% -37.75% -37.83% -56.70% -33.62% -40.53% -21.71% -38.25% -29.38% -29.54%
ROIC Less NNEP Spread (ROIC-NNEP)		 -106.01% -87.31% -40.27% -35.10% -51.33% -31.49% -37.47% -20.56% -28.81% -25.83% -25.92%
Return on Net Nonoperating Assets (RNNOA)		 94.34% 72.47% 26.95% 23.15% 29.83% 16.93% 16.58% 8.96% 11.65% 8.78% 11.71%
Return on Equity (ROE)		 -13.96% -16.68% -10.80% -14.68% -26.87% -16.69% -23.94% -12.75% -26.61% -20.60% -17.82%
Cash Return on Invested Capital (CROIC)		 -172.20% -272.98% -153.70% -164.84% -138.48% -102.19% -57.86% -47.37% -32.17% -30.53% -17.35%
Operating Return on Assets (OROA)		 -12.89% -16.33% -11.15% -14.78% -30.47% -17.26% -25.88% -14.12% -24.99% -19.86% -18.76%
Return on Assets (ROA)		 -13.86% -15.46% -5.61% -16.22% -27.09% -15.72% -22.33% -11.38% -29.89% -19.11% -18.20%
Return on Common Equity (ROCE)		 -13.96% -16.68% -10.79% -14.67% -26.86% -16.68% -23.93% -12.74% -26.59% -20.58% -17.81%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -16.47% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -0.81 -0.95 -0.89 -0.77 -1.46 -0.91 -1.44 -0.76 -1.25 -0.98 -1.13
NOPAT Margin		 -10.60% -12.54% -9.54% -9.18% -15.22% -10.19% -15.28% -8.08% -14.61% -12.08% -12.19%
Net Nonoperating Expense Percent (NNEP)		 -2.29% -1.84% 2.52% -2.73% -5.37% -2.13% -3.06% -1.15% -9.44% -3.55% -3.62%
Return On Investment Capital (ROIC_SIMPLE)		 -3.84% -3.81% -3.78% -3.09% -6.22% -4.00% -5.60% -3.14% -5.44% -4.54% -4.10%
Cost of Revenue to Revenue		 66.56% 68.78% 74.67% 66.02% 67.76% 69.33% 63.63% 67.36% 64.69% 73.04% 73.80%
SG&A Expenses to Revenue		 31.10% 17.38% 9.20% 13.40% 17.78% 17.81% 17.20% 9.65% 23.57% 14.72% 13.45%
R&D to Revenue		 10.63% 2.94% 4.69% 1.50% 1.56% 2.42% 2.09% 1.27% 0.86% 0.39% 0.14%
Operating Expenses to Revenue		 48.58% 49.13% 38.96% 47.09% 53.99% 45.23% 58.21% 44.18% 56.18% 44.22% 43.61%
Earnings before Interest and Taxes (EBIT)		 -1.16 -1.36 -0.98 -1.09 -2.43 -1.30 -2.05 -1.10 -1.79 -1.29 -1.61
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -1.12 -1.31 -0.93 -1.03 -2.36 -1.23 -1.98 -1.00 -1.69 -1.22 -1.53
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.33 0.24 0.34 0.16 0.26 0.17 0.26 0.28 0.26 0.24 0.04
Price to Tangible Book Value (P/TBV)		 0.35 0.26 0.38 0.18 0.29 0.20 0.28 0.31 0.29 0.26 0.04
Price to Revenue (P/Rev)		 0.29 0.23 0.26 0.12 0.17 0.11 0.18 0.18 0.17 0.14 0.03
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.89 -0.83 -0.67 -0.66 -0.58 -0.54 -0.44 -0.44 -0.40 -0.34 -0.45
Leverage Ratio		 1.32 1.33 1.24 1.23 1.30 1.29 1.25 1.25 1.30 1.29 1.23
Compound Leverage Factor		 1.17 1.24 1.06 1.11 1.22 1.21 1.20 1.16 1.26 1.24 1.20
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.05% 0.06% 0.05% 0.06% 0.06% 0.05% 0.05% 0.06% 0.06% 0.05%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 99.95% 99.94% 99.95% 99.94% 99.94% 99.95% 99.95% 99.94% 99.94% 99.95%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -1.00 -0.81 -0.55 -0.82 -1.00 -1.15 -0.76 -0.80 -1.15 -1.41 -1.35
Noncontrolling Interest Sharing Ratio		 0.00% 0.03% 0.03% 0.03% 0.03% 0.05% 0.05% 0.05% 0.06% 0.06% 0.05%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 4.48 4.41 4.86 5.74 4.11 4.25 5.00 4.20 4.17 4.22 5.46
Quick Ratio		 3.39 3.10 2.92 3.41 2.15 2.01 2.49 2.02 1.95 1.86 3.16
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -5.93 -8.20 -9.54 -11 -10 -8.10 -4.79 -2.77 -1.35 -1.00 0.46
Operating Cash Flow to CapEx		 0.00% -5,060.87% -469.75% -262.39% -3,318.97% -22,630.20% -795.87% -9,052.24% 0.00% -40,399.69% -13,085.92%
Free Cash Flow to Firm to Interest Expense		 -109.02 -166.64 -38,932.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -49.47 -64.76 -18,684.83 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -42.43 -66.04 -22,662.44 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.85 0.91 1.06 1.14 1.20 1.19 1.19 1.21 1.20 1.24 1.08
Accounts Receivable Turnover		 10.79 11.58 10.19 12.55 10.86 11.55 9.61 10.12 9.91 9.52 9.27
Inventory Turnover		 3.49 3.13 3.33 3.18 2.85 2.58 2.25 2.09 1.94 1.90 1.96
Fixed Asset Turnover		 63.39 69.48 67.13 71.21 76.49 78.65 61.61 62.79 65.81 68.51 63.38
Accounts Payable Turnover		 5.85 5.63 6.34 7.15 5.96 5.83 4.98 4.86 4.29 4.70 5.11
Days Sales Outstanding (DSO)		 33.82 31.52 35.83 29.09 33.60 31.59 37.97 36.06 36.84 38.34 39.36
Days Inventory Outstanding (DIO)		 104.55 116.48 109.62 114.69 128.28 141.68 162.01 174.33 187.81 192.00 186.23
Days Payable Outstanding (DPO)		 62.42 64.85 57.55 51.02 61.29 62.60 73.27 75.14 85.04 77.72 71.48
Cash Conversion Cycle (CCC)		 75.95 83.15 87.90 92.76 100.59 110.68 126.71 135.25 139.60 152.63 154.11
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 4.92 7.39 12 13 14 15 15 15 14 15 14
Invested Capital Turnover		 10.22 7.11 3.96 4.12 3.72 3.30 2.65 2.69 2.62 2.43 2.42
Increase / (Decrease) in Invested Capital		 5.11 7.25 8.65 9.76 8.90 7.19 3.35 2.01 0.10 0.03 -1.59
Enterprise Value (EV)		 -9.32 -11 -3.59 -8.30 -3.67 -4.29 -3.73 -2.51 -3.08 -1.80 -13
Market Capitalization		 6.97 6.02 7.91 3.89 6.00 3.82 6.56 6.79 6.03 5.10 1.05
Book Value per Share		 $0.83 $0.25 $1.24 $20.44 $11.75 $11.35 $5.63 $5.31 $4.69 $4.38 $5.50
Tangible Book Value per Share		 $0.77 $0.23 $1.11 $18.04 $10.24 $9.75 $5.09 $4.87 $4.31 $3.99 $5.13
Total Capital		 21 25 23 25 24 23 26 24 23 22 28
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -16 -17 -12 -12 -9.69 -8.12 -10 -9.31 -9.12 -6.91 -14
Capital Expenditures (CapEx)		 -0.38 0.06 0.97 0.52 0.10 0.01 0.16 0.01 -0.00 0.01 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 3.05 4.86 8.94 9.25 9.96 11 12 12 11 12 11
Debt-free Net Working Capital (DFNWC)		 19 22 20 21 20 19 22 21 20 19 25
Net Working Capital (NWC)		 19 22 20 21 20 19 22 21 20 19 25
Net Nonoperating Expense (NNE)		 0.44 0.34 -0.39 0.42 0.70 0.27 0.33 0.12 0.89 0.27 0.44
Net Nonoperating Obligations (NNO)		 -16 -17 -11 -12 -9.69 -8.12 -10 -9.31 -9.12 -6.91 -14
Total Depreciation and Amortization (D&A)		 0.04 0.04 0.05 0.06 0.07 0.06 0.07 0.10 0.10 0.08 0.08
Debt-free, Cash-free Net Working Capital to Revenue		 12.64% 18.19% 29.33% 28.05% 28.57% 29.24% 32.94% 32.18% 31.09% 33.79% 31.96%
Debt-free Net Working Capital to Revenue		 80.27% 83.39% 67.09% 65.09% 56.35% 51.66% 61.30% 57.11% 56.22% 53.26% 70.86%
Net Working Capital to Revenue		 80.27% 83.39% 67.09% 65.09% 56.35% 51.66% 61.30% 57.11% 56.22% 53.26% 70.86%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($118,280.00) ($40.00) $0.00 ($0.94) ($45.00) ($4.40) ($3.90) ($0.19) ($4.50) ($2.50) ($1.15)
Adjusted Weighted Average Basic Shares Outstanding		 6.00 32.07K 0.00 1.27M 70.18K 270.33K 449.61K 4.56M 415.71K 490.60K 1.37M
Adjusted Diluted Earnings per Share		 ($118,280.00) ($40.00) $0.00 $0.00 ($45.00) ($4.40) $0.00 $0.00 ($4.50) $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 6.00 32.07K 0.00 2.00M 270.75K 270.33K 455.60K 4.91M 0.00 500.60K 3.88M
Adjusted Basic & Diluted Earnings per Share		 ($118,280.00) $0.00 $0.00 $0.00 ($45.00) $0.00 $0.00 $0.00 ($4.50) $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 49.73K 947.25K 0.00 2.00M 270.75K 455.60K 455.60K 4.91M 0.00 500.60K 3.88M
Normalized Net Operating Profit after Tax (NOPAT)		 -0.73 -0.79 -0.73 -0.69 -1.24 -0.89 -0.65 -0.24 -1.18 -0.91 -0.90
Normalized NOPAT Margin		 -9.45% -10.48% -7.86% -8.20% -12.95% -9.98% -6.90% -2.52% -13.79% -11.31% -9.69%
Pre Tax Income Margin		 -13.41% -16.73% -9.01% -11.65% -23.83% -13.71% -21.04% -10.84% -20.20% -15.38% -16.88%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -21.39 -27.58 -4,007.11 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -14.97 -19.22 -3,623.65 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -14.36 -28.86 -7,984.71 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -7.94 -20.50 -7,601.25 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -12.01% -77.65% -86.26% -74.29% -61.15% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Sunshine Biopharma’s financial statements show a business with growing cash resources but continued operating losses and recurring cash burn. The company’s results improved in some areas during the second quarter of 2026, although profitability remains a distant objective.

  • Revenue increased sequentially: Q2 2026 revenue was $9.3 million, up from $8.1 million in Q1 2026. The company also remained above the $7.5 million reported in Q1 2024, indicating that its revenue base has expanded over the longer term.
  • Operating cash burn improved in Q2 2026: Net cash used in operating activities declined to $918,000 from $2.1 million in Q1 2026 and $1.3 million in Q2 2025.
  • Cash increased substantially: Cash and equivalents rose to $13.7 million at June 30, 2026, from $6.9 million at the end of Q1. The increase was primarily supported by $7.8 million of financing cash flow.
  • Balance-sheet liquidity remains strong: Current assets of $30.7 million substantially exceeded current liabilities of $5.6 million, producing a current ratio of roughly 5.5. Total liabilities were only $6.1 million compared with $27.5 million of common equity.
  • Quarterly losses have generally improved from 2024 levels: The Q2 2026 net loss from continuing operations was $1.6 million, compared with losses of $2.2 million in Q4 2024 and $1.8 million in Q2 2025.
  • Revenue growth has been uneven: Q2 2026 revenue was slightly below the $9.4 million reported in Q2 2025, while Q4 2025 revenue was below Q4 2024. The recent sequential improvement therefore has not yet established a consistent growth trend.
  • Financing is an important source of liquidity: The Q2 cash increase came overwhelmingly from financing rather than operations. This provides near-term flexibility, but the sustainability of the balance-sheet improvement depends on whether the company can reduce its operating losses.
  • Sunshine Biopharma remains unprofitable: Q2 2026 operating income was negative $1.6 million, and net loss attributable to common shareholders was $1.9 million, or negative $1.15 per basic share.
  • Gross margins have deteriorated: Gross profit was $2.4 million on $9.3 million of revenue in Q2 2026, implying a margin of approximately 26%. That compares with roughly 36% in Q2 2025 and 32% in Q4 2025. Operating expenses of $4.0 million exceeded gross profit by approximately $1.6 million.
  • Accumulated losses and potential dilution remain significant risks: Retained earnings were negative $77.8 million at June 30, 2026. Common stock increased to $106.0 million from $98.1 million in Q1 2026, suggesting continued equity financing and possible dilution for existing shareholders. Reported share counts also vary widely across periods and include restated figures, making per-share comparisons more difficult.

Overall, the second quarter brought better sequential revenue and operating cash-flow results, while the stronger cash position reduces immediate liquidity pressure. However, Sunshine Biopharma still relies heavily on financing, has not produced positive operating cash flow in the reported periods, and faces pressure from declining gross margins, recurring losses and a large accumulated deficit.

11/13/26 05:09 AM ETAI Generated. May Contain Errors.

Sunshine Biopharma Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Sunshine Biopharma's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Sunshine Biopharma's net income appears to be on a downward trend, with a most recent value of -$5.98 million in 2025, falling from -$1.65 million in 2015. The previous period was -$5.13 million in 2024. View Sunshine Biopharma's forecast to see where analysts expect Sunshine Biopharma to go next.

Sunshine Biopharma's total operating income in 2025 was -$6.23 million, based on the following breakdown:
  • Total Gross Profit: $12.26 million
  • Total Operating Expenses: $18.48 million

Over the last 10 years, Sunshine Biopharma's total revenue changed from $1.71 thousand in 2015 to $36.31 million in 2025, a change of 2,125,537.6%.

In the past 9 quarters, Sunshine Biopharma's cash and equivalents has ranged from $6.91 million in Q1 2026 to $17.43 million in Q1 2024, and is currently $13.75 million as of their latest financial filing in Q2 2026.

Sunshine Biopharma had total debt of $0.00 at the end of 2025, compared with none in 2024, and a 100.0% decrease since 2015.

Over the last 10 years, Sunshine Biopharma's book value per share changed from 0.00 in 2015 to 4.69 in 2025.


Related Companies

Financial statements for NASDAQ:SBFM last updated on 10/26/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...
Base Camp Trading | Sponsoredtc pixel
Trump’s EO to send this $5 stock ripping higher…?
President Trump's December executive order declared space a national security and economic priority, fueling a...
Traders Agency | Sponsoredtc pixel
Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...
Behind the Markets | Sponsoredtc pixel
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel
URGENT: If you own a home, please review the map below.
More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...
Paradigm Press | Sponsoredtc pixel
Uranium Mine Flood That Sparked a 2006 Price Surge Returns
In 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...
Digest Publishing | Sponsoredtc pixel
Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...
Weiss Ratings | Sponsoredtc pixel